Michael G. Kauffman
2017
In 2017, Michael G. Kauffman earned a total compensation of $2.7M as Chief Executive Officer at Karyopharm Therapeutics, a 73% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $251,503 |
|---|---|
| Option Awards | $1,857,650 |
| Salary | $530,500 |
| Other | $11,460 |
| Total | $2,651,113 |
Kauffman received $1.9M in option awards, accounting for 70% of the total pay in 2017.
Kauffman also received $251.5K in non-equity incentive plan, $530.5K in salary and $11.5K in other compensation.
Rankings
In 2017, Michael G. Kauffman's compensation ranked 4,190th out of 14,666 executives tracked by ExecPay. In other words, Kauffman earned more than 71.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,190 out of 14,666 | 71st |
Division Manufacturing | 1,467 out of 5,768 | 75th |
Major group Chemicals And Allied Products | 420 out of 2,074 | 80th |
Industry group Drugs | 321 out of 1,730 | 81st |
Industry Pharmaceutical Preparations | 255 out of 1,329 | 81st |
Source: SEC filing on April 27, 2018.
Kauffman's colleagues
We found two more compensation records of executives who worked with Michael G. Kauffman at Karyopharm Therapeutics in 2017.
News
Karyopharm Therapeutics CEO Richard Paulson receives $8.4M in 2021
April 8, 2022
Karyopharm Therapeutics CEO Michael Kauffman's 2020 pay jumps 22% to $3.9M
April 7, 2021
Karyopharm Therapeutics CEO Michael Kauffman's 2019 pay jumps 42% to $3.2M
April 9, 2020
Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer Anand Varadan receives $2.3M in 2018
April 19, 2019